MAOI (Irreversible Monoamine Oxidase Inhibitor)
Pregnancy: Avoid — risk to fetus (neonatal hypotension, growth retardation). Use under specialist guidance only if no alternative.
Phenelzine
Brand names: Nardil
Adult dose
Dose: Depression (treatment-resistant / atypical): 15mg TDS initially; increase over 2–4 weeks to 15–30mg TDS; usual maintenance 15mg BD–TDS. After remission, reduce slowly to minimum effective dose (often 15mg OD).
Route: Oral
Frequency: Two to three times daily
Max: 90mg daily (under specialist supervision)
Irreversible, non-selective MAO-A and MAO-B inhibitor. Requires 14-day washout before starting any serotonergic drug. Mandatory dietary tyramine restriction (aged cheese, cured meats, fermented foods, Marmite, soy sauce, broad beans) — 'cheese reaction' risk. Used only by specialists for treatment-resistant or atypical depression unresponsive to other antidepressants.
Paediatric dose
Route: Oral
Frequency: Three times daily
Max: Not applicable
Not licensed under 18 years. Seek specialist child and adolescent psychiatry opinion. Rarely used in this age group.
Dose adjustments
Renal
Use with caution — limited data. Avoid in severe renal impairment.
Hepatic
Contraindicated in hepatic impairment — hepatotoxicity risk; abnormal LFTs are a contraindication.
Clinical pearls
- 14-day washout in BOTH directions: wait 14 days after stopping phenelzine before starting any serotonergic drug; wait 14 days after stopping most antidepressants before starting phenelzine (except fluoxetine — 5-week washout required due to long half-life)
- Dietary counselling is mandatory — provide written tyramine-restricted diet list; ensure patient understands the risk of hypertensive crisis from dietary tyramine
- Antidote for hypertensive crisis (cheese reaction): IV phentolamine (alpha-blocker) or oral nifedipine; avoid beta-blockers alone (leaves alpha-receptor unopposed)
- Phenelzine is reserved for treatment-resistant depression under specialist supervision — particularly effective in atypical depression (reverse vegetative features: hypersomnia, hyperphagia, mood reactivity, rejection sensitivity)
Contraindications
- Hepatic impairment
- Cerebrovascular disease
- Phaeochromocytoma
- Concomitant SSRIs, SNRIs, TCAs, other MAOIs, pethidine, tramadol, sympathomimetics, dextromethorphan — risk of life-threatening interactions
- Hypersensitivity to phenelzine
Side effects
- Hypertensive crisis (cheese reaction — dietary tyramine)
- Orthostatic hypotension (common)
- Dizziness, headache
- Insomnia or sedation
- Oedema
- Sexual dysfunction
- Weight gain
- Hepatotoxicity (rare)
- Hyperpyrexia
- Myoclonic jerks
Interactions
- SSRIs, SNRIs, TCAs, other MAOIs — serotonin syndrome / hypertensive crisis — CONTRAINDICATED; 14-day washout required (both ways)
- Pethidine — potentially fatal (excitatory reaction — hyperpyrexia, seizures, coma); all opioids should be used with caution (morphine/fentanyl safest alternatives at lowest doses)
- Sympathomimetics (ephedrine, pseudoephedrine, OTC cold remedies) — hypertensive crisis
- Dextromethorphan (in cough remedies) — serotonin syndrome
- Levodopa — hypertension
- Insulin/antidiabetics — phenelzine enhances hypoglycaemic effect
Monitoring
- Blood pressure (orthostatic and lying)
- LFTs (phenelzine is hepatotoxic — monitor at baseline and periodically)
- Dietary adherence review at each appointment
- Mood response
Reference: BNFc; BNF 90; Maudsley Prescribing Guidelines (13th Ed). Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF